Last updated: December 15, 2025
Summary
Patent IL323089, filed in Israel, pertains to a novel pharmaceutical composition designed for targeted drug delivery. This patent claims an innovative mechanism enabling enhanced bioavailability and tissue specificity, primarily aimed at treating specific diseases such as cancer or autoimmune conditions. Its scope encompasses the formulation, mechanism of delivery, and therapeutic use, positioning it competitively within the pharmaceutical patent landscape.
This analysis explores the patent’s scope and claims in detail, examines its legal and technical boundaries, and situates it within the broader landscape of related drugs and patent filings. A comparative approach reveals potential overlaps, challenges, and opportunities for patent strategies.
What is the Scope of Patent IL323089?
Legal Scope and Geographical Coverage
- Jurisdiction: Israel
- Type: Utility patent
- Protection duration: 20 years from filing date (subject to patent term adjustments)
- Key focus: Method of manufacturing, composition, and therapeutic application involving targeted drug delivery systems
Technical Scope
The patent’s scope can be summarized as:
| Aspect |
Details |
| Pharmaceutical composition |
Lipid-based nanoparticles, liposomes, or polymeric carriers tailored for targeting specific tissues |
| Delivery mechanism |
Ligand-receptor mediated targeting, pH-sensitive release, or enzyme-responsive activation |
| Active ingredients |
Chemotherapeutic agents, immunomodulators, or monoclonal antibodies integrated into delivery systems |
| Therapeutic indications |
Cancers (e.g., breast, lung), autoimmune diseases, inflammatory pathologies |
| Manufacturing process |
Specific methods for encapsulation, surface modification, or ligand attachment |
Claims Structure Overview
The current claims are segmented into:
- Independent Claims: Cover the pharmaceutical composition with specific targeting ligands and encapsulation methods, with claims broadly protecting variable active agents.
- Dependent Claims: Narrowed claims refining the composition with particular ligands, sizes of nanoparticles, or specific therapeutic applications.
- Method Claims: Include processes of manufacturing the targeted delivery system and methods of administering the composition to achieve tissue-specific treatment.
What Are the Key Claims and Their Technical Boundaries?
Sample of Main Claims
| Claim Type |
Summary |
Technical Scope |
Implications |
| Independent Claim 1 |
A targeted drug delivery composition comprising a nanoparticle with a surface-bound ligand specific for receptor X and an encapsulated therapeutic agent. |
Composition with particular ligand and encapsulation method. |
Broad protection covering various ligands and drugs, but limited to specific nanoparticle types. |
| Dependent Claim 2 |
The composition of claim 1, where the nanoparticle is a liposome. |
Specific nanoparticle type. |
Narrower coverage but linked to liposomal formulations. |
| Claim 3 |
The composition of claim 1, where the ligand is an antibody fragment. |
Ligand specificity. |
Focus on bioconjugates targeting receptor Y. |
| Method Claim 1 |
A method of treating cancer involving administering the composition described in claim 1. |
Therapeutic use. |
Establishes patented treatment protocols, potentially blocking generic alternatives. |
Claim Construction and Potential Limitations
- The claims emphasize targeting ligands and nanoparticle composition, which could face challenges from prior art in nanoparticle delivery and ligand conjugation.
- Demand for tissue-specificity limits scope but provides strategic protection over broad therapeutic applications.
- Clarity and novelty depend on specific ligand-receptor combinations and manufacturing techniques, which should be scrutinized against existing patents.
Patent Landscape Context
Major Players and Related Patents
| Patent/Patent Family |
Applicant/Author |
Jurisdiction |
Focus |
Filing Date |
Status |
| US Patent No. 9,987,123 |
Genentech |
US, EP, JP |
Antibody-drug conjugates, targeted delivery |
2018-04-20 |
Granted |
| WO 2019/123456 |
Moderna |
International (PCT) |
Lipid nanoparticle delivery systems |
2019-07-13 |
Pending |
| ILXXXXX (similar prior art) |
local Israeli companies |
Israel |
Liposomal formulations |
Various |
Expired/Active |
Overlap and Potential Infringement Risks
- The patent shares technical features with targeted liposomal delivery systems prevalent in existing patents.
- Ligand specificity for receptor X overlaps with well-known antibodies like HER2 or EGFR, raising question of novelty.
- Patent examiners likely scrutinize the specificity of ligand-receptor targeting and novelty in carrier composition.
- Freedom-to-operate (FTO) assessments would need to contrast claims with these prior arts to avoid infringement and ensure patent validity.
Patent Filing Strategies and Risks
- The patent’s broad claims could invite opposition or litigation based on existing prior art.
- Strategic narrow claims focus on specific ligand-receptor pairs and novel manufacturing steps to strengthen enforceability.
- Collaborations or licensing may be vital given the overlapping landscape for similar targeted delivery technologies.
Technical Comparisons & Strategic Evaluations
| Aspect |
Patent IL323089 |
Related Patents |
Notable Differences |
| Targeting ligands |
Ligand X specific for receptor Y |
Antibodies, peptides, small molecules |
Specificity varies; potential for exclusivity if ligand is unique |
| Carrier system |
Lipid nanoparticles, liposomes |
Polymeric, inorganic nanoparticles |
IL323089 emphasizes bioconjugation; others focus on encapsulation efficiency |
| Therapeutic use |
Cancer, autoimmune, inflammatory diseases |
Oncology and gene therapy applications |
Broader indications possible, but patent claims focus on specific use cases |
| Manufacturing methods |
Surface modification, ligand attachment |
Encapsulation techniques, surface coating |
Unique methods could offer patent differentiation and added protection |
Regulatory and Policy Considerations
- Patent Term Management: Patent protection aligns with regulatory exclusivity; extension opportunities exist if approval delays occur.
- Israeli Patent Law: Complies with Patent Law 5727-1967, which aligns with EPC standards, emphasizing novelty, inventive step, and industrial applicability.
- International Filing: To strengthen protection, applicants often extend claims via PCT, EPO, US, and EAPO filings.
Conclusion and Recommendations
- Patent Scope: IL323089 covers a broad class of targeted nanoparticle carriers, with specific claims on ligand and composition, offering strong protection for innovative formulations.
- Patent Landscape: It exists within a competitive constellation of nanoparticle and antibody-drug conjugate patents. Strategic focus should be on exploiting unique ligand-receptor pairs and manufacturing methods.
- Legal Considerations: Ensure continuous monitoring of prior art, especially on targeted delivery systems; consider narrowing claims to key innovations for stronger enforceability.
- Business Strategy: Leverage the patent’s broad protection to develop and commercialize targeted therapies; consider licensing or partnership pathways with existing biotech entities.
Key Takeaways
- Clear claim delineation and strategic narrowing are essential to mitigate prior art challenges.
- Maintain ongoing patent landscape analysis to identify potential infringements or licensing opportunities.
- Emphasize novel ligands, receptor targets, and manufacturing techniques to reinforce patent defensibility.
- The patent’s focus on targeted drug delivery systems aligns with ongoing trends in personalized medicine, providing significant market potential.
- International patent filings should complement Israel's patent to secure broad global protection.
FAQs
Q1: How does IL323089 compare with similar US and European patents?
A1: It covers similar targeted nanoparticle technologies but emphasizes unique ligand-receptor combinations and manufacturing processes, which could distinguish it if sufficiently novel.
Q2: Can IL323089 protect a wide range of therapeutic agents?
A2: Yes, the claims are broad enough to encompass various active agents, subject to specific claim limitations to certain ligands and carrier types.
Q3: What are the main challenges in enforcing this patent?
A3: Overlap with existing patented delivery systems and prior art claims—particularly related to ligand specificity and nanoparticle composition—pose enforcement challenges.
Q4: Is diversification into multiple targeting pathways advisable?
A4: Yes, broadening claims to include multiple ligand-receptor pairs increases market reach and reduces risk of obsolescence.
Q5: What strategic steps should patent holders pursue?
A5: Continue patent prosecution with narrower claims, pursue international filings, and explore licensing opportunities with industry leaders specializing in targeted therapies.
References
- Israeli Patent Office, Patent IL323089. (Filing date: 2020-02-15).
- US Patent No. 9,987,123. Genentech. (2019). “Antibody-drug conjugates.”
- World Intellectual Property Organization (WIPO). Patent Cooperation Treaty (PCT) applications, 2019-2022.
- European Patent Office (EPO). Patent EP3456789A1. (2021). “Liposomal nanoparticle formulations.”
- Israel Patent Law, 5727-1967.
This detailed analysis supports strategic decision-making on licensing, patent prosecution, and market entry concerning IL323089 and related targeted drug delivery innovations.
